Specifically targeting signaling proteins and kinases in the PI3K/AKT1/mTOR cascade may help develop novel therapeutic approaches for idiopathic and associated PAH, as well as PH associated with lung diseases and hypoxia. The gene discussed is AKT1; the disease is pulmonary arterial hypertension.